2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

FiercePharma
New BD survey finds nearly half of women unaware of STI treatment options
Smiling woman smiling while painting
STIs | Vaginitis | Brochures
Vaginitis and STIs: The right treatment begins with the right diagnosis
ReachMD: Genotype specific persistence: Looking beyond HPV 16
Cervical Cancer | Webinars & Videos
ReachMD: Genotype specific persistence: Looking beyond HPV 16